From 1519 newly diagnosed HIV individuals seen in Madrid between the years 2000 and 2008, 65 (4.3%) were HBsAg+. Two HIV/HBV-coinfected patients showed the lamivudine resistance mutation M204V in HBV while no drug resistance mutations were recognized in HIV. None of them admitted prior exposure to antiretroviral drugs. Thus, HIV/HBV-coinfected patients might benefit from baseline drug resistance testing for both HIV and HBV to optimize the selection of anti-HBV active antiviral therapy.
Get full access to this article
View all access options for this article.
References
1.
KonopnickiD, MocroftA, de WitSet al.Hepatitis B and HIV: Prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. AIDS, 2005; 19:2117–2125.
2.
SorianoV, PuotiM, PetersMet al.Care of HIV patients with chronic hepatitis B: Updated recommendations from the HIV-HBV International panel. AIDS, 2008; 22:1399–1410.
3.
KozielM, PetersM. Viral hepatitis in HIV infection. N Engl J Med, 2007; 356:1445–1454.
4.
ThioC, SeabergE, SkolaskyRet al.HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS)Lancet, 2002; 360:1921–1926.
5.
HammerS, EronJ, ReissPet al.Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA, 2008; 300:555–570.
6.
DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescentsNovember 3, 2008www.aidsinfo.nih.gov.
7.
RockstrohJ, BhaganiS, BenhamouYet al.EACS guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med, 2008; 9:82–88.
8.
KeeffeE, DieterichD, HanSet al.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol, 2008; 6:1315–1341.
9.
LittleS, HolteS, RoutyJet al.Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med, 2002; 347:385–394.
10.
WensingA, BoucherC. Worldwide transmission of drug-resistant HIV. AIDS Rev, 2003; 5:140–155.
11.
de MendozaC, RodriguezC, ColominaJet al.Resistance to non-nucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis, 2005; 41:1350–1354.
12.
FoxJ, DustanS, McClureM, WeberJ, FidlerS. Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy. HIV Med, 2006; 7:477–483.
13.
LudwigA, GoebelT, AdamsOet al.Primary resistance mutations against nucleos(t)ide analogues in treatment naïve patients with HBV infection. American Association for the Study of Liver Diseases: San FranciscoNovember 2008 [abstract 884].
14.
FungS, MazulliT, El-KashabM, ShermanM, PopovicV. Lamivudine-resistant mutation among treatment-naive hepatitis B patients is common may be associated with treatment failure. American Association for the Study of Liver Diseases: San FranciscoNovember 2008 [abstract 888].
15.
ThioC, LocarniniS. Treatment of HIV/HBV coinfection: Clinical and virologic issues. AIDS Rev, 2007; 9:40–53.
16.
JardiR, Rodriguez-FriasF, TaberneroDet al.Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy. J Clin Microbiol, 2009; 47:485–488.
17.
de MendozaC, RodriguezC, ColominaJet al.Resistance to non-nucleoside reverse transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis, 2005; 41:1350–1354.
18.
ModiA, FeldJ. Viral hepatitis and HIV in Africa. AIDS Rev, 2007; 9:25–39.
19.
HoffmannC, CharalambousS, MartinDet al.Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis, 2008; 47:1479–1485.
20.
ThibaultV, Aubron-OlivierC, AgutH, KatlamaC. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS, 2002; 6:131–133.
21.
GerettiAM. on behalf of the SURF Study Group: Multicentre surveillance study of HBV infection in HIV+ patients: Evidence of transmitted, acquired HBV drug resistance. 7th European HIV Drug Resistance Workshop: Stockholm, SwedenMarch 2009 [abstract 38].
22.
BenhamouY, BochetM, ThibaultVet al.Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology, 1999; 30:1302–1306.
23.
SorianoV, RivasP, NuñezM. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. Clin Infect Dis, 2008; 47:1486–1489.
24.
SorianoV, PerelsonA, ZoulimF. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?J Antimicrob Chemother, 2008; 62:1–4.
25.
SheldonJ, CorralA, RodesBet al.Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS, 2005; 19:2036–2038.
26.
SheldonJ, CaminoN, RodesB, BartholomeuszA, KuiperM, TackeFet al.Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther, 2005; 10:727–734.
27.
SheldonJ, RodesB, ZoulimF, BartholomeuszA, SorianoV. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat, 2006; 13:427–434.
